No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
INSM240517C27500
- 1.20
- -0.30-20.00%
15min DelayTrading May 9 15:06 ET
2.00High1.20Low
2.00Open1.50Pre Close2 Volume4 Open Interest27.50Strike Price320.00Turnover95.31%IV9.13%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry1.20Time Value100Contract SizeAmericanOptions Type0.4076Delta0.1023Gamma22.36Leverage Ratio-0.0918Theta0.0022Rho9.11Eff Leverage0.0155Vega
Intraday
- 5D
- 1D
News
Insmed's Q1 Net Loss Narrows as Revenue Advances
Insmed (INSM) reported a Q1 net loss Thursday of $1.06 per diluted share, narrowing from a loss of $1.17 a year earlier. Analysts surveyed by Capital IQ expected a loss of $1.24. Revenue for the quart
Insmed Q1 2024 GAAP EPS $(1.06) Beats $(1.23) Estimate, Sales $75.500M Miss $77.758M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.23) by 13.82 percent. This is a 9.4 percent increase over losses of $(1.17) per sha
Express News | Insmed Inc - Reiterates 2024 Global Arikayce Revenue Guidance in Range of $340 Mln to $360 Mln
Insmed | 10-Q: Quarterly report
Express News | Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
Express News | Insmed Q1 Revenue USD 75.5 Million Vs. Ibes Estimate USD 77.8 Million
Comments
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The Wells Fargo equity team identified 14 high-conviction, catalyst-driven stock opportunities for the second quarter, including two Magnificent 7 names: Amazon and Tesla.
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
10
1
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Insiders at Insmed selling shares may indicate they believe the shares are overpriced. Some alignment exists between management and smaller shareholders, but lack of recent insider buying and net selling over the past year raises concerns.
1
Insmed's overvaluation and slower than average forecasted revenue growth raise investors' concern. Despite hopes for a turnaround, analysts express less confidence, indicating risks for shareholders and potential investors.
Read more